insulin glulisine · Apidra
Peptide
Evidence outlook
Approved: Type 2 Diabetes, Type 1 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Diabetes mellitus requiring insulin therapy
- Treatment of adults, adolescents and children, six years or older with diabetes mellitus
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00290927 NCT00290927 · Diabetes Mellitus, Type 2 The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met. Registry: NCT00290927 | 3 | Efficacy: change in HbA1C from baseline to endpoint (superiority of HMR1964 and OHA combination therapy as compared to OHA therapy, superiority of HMR1964 mono-therapy as compared to OHA therapy); Safety of HMR1964 | Results not posted; external-source review pending | Partial signal | link ↗ |
View 1 more trial
NCT00135057 NCT00135057 · Diabetes Mellitus, Type 2 The study was randomized and included 281 participants, but it was open-label and used A1c, a surrogate measure rather than a hard clinical endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT00135057 | 3 | Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count | Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (36)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (4)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 4 (1)
What this study did
Competitive landscape
Other Insulin receptor drugs
insulin aspart, Insulin aspart (Fiasp), Insulin Lispro, Insulin lispro (Lyumjev), insulin NPH and 3 more. Compare all 9 Insulin receptor drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Insulin Glulisine (Apidra): this drug | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Afrezza | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis). | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Basaglar) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Toujeo) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Human | Approved | — | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cadisegliatin | Phase 3 | Small molecule | Glucokinase | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zimislecel | Phase 3 | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary in this indication | |
| Icovamenib | Phase 2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.